Company Overview
Snapshot
Founded in January 2017 by Yaakov Nahmias, Tissue Dynamics operates with 11–50 employees. The company has secured $3.26M across two funding rounds. In February 2024, Tissue Dynamics announced a strategic collaboration with ATCC to bring a transformative heart organoid model to market.
Business overview
Tissue Dynamics is a biotechnology company focused on transforming drug and cosmetic development through advanced organ-on-chip (OOC) tools. The company's bionic OOC platform provides 3D microphysiological models that emulate human physiology with real-time monitoring and smart algorithm analysis. This technology aims to increase clinical success rates and reduce R&D costs for the pharmaceutical, nutraceutical, and cosmetic industries by offering human-relevant models and sensor-driven discovery.
Strategic signal
In May 2026, Tissue Dynamics announced a collaboration with Galmed Pharmaceuticals to develop a human-centered chronic cardiac fibrosis platform. This partnership is significant as it aims to advance Aramchol-based therapeutics, signaling the company's continued expansion into therapeutic development and its commitment to addressing complex diseases through its innovative OOC technology.
Log in to access full profile ›Company Intelligence Q&A
- What is Tissue Dynamics' core focus?
- Tissue Dynamics is committed to transforming drug and cosmetic development by advancing next-generation organ-on-chip (OOC) tools for the pharmaceutical, nutraceutical, and cosmetic industries.
- When was Tissue Dynamics founded?
- Tissue Dynamics was founded in January 2017.
- What significant collaboration did Tissue Dynamics announce in February 2024?
- In February 2024, Tissue Dynamics announced a strategic collaboration with ATCC to bring a transformative heart organoid model to market.
- What is the total capital raised by Tissue Dynamics?
- Tissue Dynamics has raised a total of $3.26M across two funding rounds.
- What recent partnership did Tissue Dynamics form to advance cardiac fibrosis therapeutics?
- In May 2026, Tissue Dynamics partnered with Galmed Pharmaceuticals to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics.